AIDS prevention pill study halted; no benefit seen

Apr 18, 2011 By MARILYNN MARCHIONE , AP Medical Writer

Researchers are stopping a study that tests a daily pill to prevent infection with the AIDS virus in thousands of African women because partial results show no signs that the drug is doing any good.

Women taking Truvada (true-VAH'-duh), made by Gilead Sciences Inc., are just as likely to get HIV as other women who have been given dummy pills, an interim analysis of the study found. Even if the study were to continue, it would not be able to determine whether the pills help prevent infection, since the results are even this far along, researchers said.

The finding is disappointing because another study last fall concluded that Truvada did help prevent infections in gay and when given with , counseling and other prevention services. Many AIDS experts view that as a breakthrough that might help slow the epidemic.

Family Health International, a nonprofit involved in AIDS research, announced the new results on Monday. The group launched the study two years ago and had enrolled about half of the 3,900 women intended in Kenya, Tanzania and South Africa. As of last week, 56 new HIV infections had occurred, half in each group.

No safety problems were seen with Truvada. However, women taking it were more likely to become pregnant than those on dummy pills.

"That's both a surprising finding and one that we can't readily explain" by what is known so far about Truvada's effects on women using , said Dr. Timothy Mastro of Family Health International. The study was sponsored by the U.S. Agency for International Development and the Bill & Melinda Gates Foundation. Gilead provided the drugs for the study.

Truvada already is sold for treating HIV. It's a combination of two drugs, tenofovir and emtricitabine, or FTC, made by California-based Gilead Sciences Inc.

Using it or its components for prevention is still "very promising," Mastro said, although benefits and risks may vary by gender and by the way the virus is spread - sex between men and women or riskier anal sex among men, for example.

Last year, a study in South Africa found that a vaginal gel spiked with tenofovir cut in half a woman's chances of getting HIV from an infected partner. Protection was greater for those who used it most faithfully.

A similar effect was seen in the study of Truvada in gay men. The drug lowered the chances of infection by 44 percent, and by 73 percent or more among men who took their pills most faithfully. The U.S. Centers for Disease Control and Prevention recently gave advice to doctors on prescribing Truvada along with other prevention services for gay men, based on those encouraging results.

In the new study, "it's difficult to understand why they did not see protection," but blood samples may tell more about whether it's related to how faithfully women took the pills, said Dr. Robert M. Grant of the Gladstone Institutes, a private foundation affiliated with the University of California, San Francisco.

He led the study of Truvada in and said, "we are very confident that this approach is useful" for them.

The new study's result "must be seen as what it is - the closure of a single trial in a field that has generated exciting results in the recent past," said Mitchell Warren, head of the AIDS Vaccine Advocacy Coalition, a nonprofit group that works on prevention research.

Two other large studies testing drugs for prevention are under way in Africa, in heterosexual and in couples where one has the and the other does not. Results are expected within two years. The studies have mostly been in countries with high rates of new infections because that makes it easier to see whether a prevention measure is having an impact.

Truvada costs $5,000 to $14,000 a year in the United States, but as little as $140 a year in some poor countries where it's available in generic form.

Explore further: Harm-reduction program optimizes HIV/AIDS prevention

More information:
CDC: www.cdc.gov/hiv/prep/resources/qa/index.htm

AIDS information: www.aidsinfo.nih.gov

and www3.niaid.nih.gov/topics/HIVAIDS/

not rated yet
add to favorites email to friend print save as pdf

Related Stories

3 big developments make AIDS outlook more hopeful

Nov 23, 2010

(AP) -- In the nearly 30 years the AIDS epidemic has raged, there has never been a more hopeful day than this. Three striking developments took place Tuesday: U.N. officials said new HIV cases are dropping ...

Daily dose of HIV drug reduces risk of HIV infection

Nov 23, 2010

A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention ...

AIDS drug trials may be virus stopper

May 18, 2006

A U.S. pharmaceutical company is trying to get complete human data on a drug proven to prevent HIV in monkeys more than 12 years ago.

Recommended for you

Harm-reduction program optimizes HIV/AIDS prevention

3 hours ago

(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments : 0

More news stories